Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Esperion Therapeutics, Inc. (ESPR)
USD3.18
+0.00 (+0.00%)
US NASDAQ Healthcare Biotechnology
Address
3891 Ranchero Drive 48108
Ann Arbor, MI, US
Ann Arbor, MI, US
CEO
Sheldon L. Koenig
Website
esperion.com
IPO
2013-06-26
CIK 1434868 ISIN US29664W1053
Also trades on
London Stock Exchange · 0IIM.L (USD)
NASDAQ Global Market · ESPR (USD)
Description
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.18
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
14M
Beta
1.06
Float Shares
207.91M
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -0.32% | +40.99% | -8.75% | +5.74% | -15.41% | +300.92% | +84.12% | -86.03% | -78.72% | -78.41% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (25 ratings, all time)
Hold
Price Targets & DCF
Current price
3.18
Low
3.16
-0.6%
Consensus
3.19
+0.3%
Median
3.16
-0.6%
High
3.28
+3.1%
Ratings Trend (MoM)
46% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 3 | 0 |
| Hold | 6 | +5 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 4 |
3.19
+0.3%
|
| Last Quarter | 4 |
3.19
+0.3%
|
| Last Year | 6 |
5.13
+61.3%
|
| All Time | 9 |
7.86
+147.2%
|
Quality scores
Altman Z-Score
-2.62
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+21.3% ★ Q1'26: +23.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+60.7% ★ Q1'26: +52.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-10.1% Q1'26: -34.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+15.0% ★ Q1'26: -8.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+77.1% ★ Q1'26: +12.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+11.1% Q1'26: +28.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×9.09× Q1'26: -9.60× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
148.36M
est: 148.13M (+0.2%)
|
227.55M
est: 230.35M (-1.2%)
|
78.45M
est: 77.81M (+0.8%)
|
75.48M
est: 77.23M (-2.3%)
|
116.33M
est: 277.79M (-58.1%)
|
332.31M
est: 324.76M (+2.3%)
|
403.14M
est: 402.24M (+0.2%)
|
387.81M
357.41M – 426.06M
-3.6% YoY
|
448.84M
395.38M – 485.97M
+15.7% YoY
|
553.23M
546.35M – 560.11M
+23.3% YoY
|
884.55M
740.34M – 1.01B
+59.9% YoY
|
1.12B
938.91M – 1.29B
+26.8% YoY
|
| EBITDA |
-88.73M
est: 7.23M (-1,327.1%)
|
-120.33M
est: -190.27M (+36.8%)
|
-222.14M
est: -208.68M (-6.5%)
|
-176.35M
est: -227.67M (+22.5%)
|
-150.11M
est: -157.10M (+4.5%)
|
7.57M
est: -183.67M (+104.1%)
|
60.27M
est: -227.49M (+126.5%)
|
-219.32M
-240.96M – -202.13M
+3.6% YoY
|
-253.84M
-274.84M – -223.61M
-15.7% YoY
|
-312.87M
-316.76M – -308.98M
-23.3% YoY
|
-500.25M
-573.78M – -418.69M
-59.9% YoY
|
-634.43M
-727.67M – -530.99M
-26.8% YoY
|
| EBIT |
-89.05M
est: 2.70M (-3,396.1%)
|
-120.88M
est: -191.33M (+36.8%)
|
-222.76M
est: -214.13M (-4.0%)
|
-176.85M
est: -234.29M (+24.5%)
|
-150.27M
est: -157.13M (+4.4%)
|
7.51M
est: -183.70M (+104.1%)
|
60.27M
est: -227.52M (+126.5%)
|
-219.36M
-241.00M – -202.16M
+3.6% YoY
|
-253.88M
-274.88M – -223.64M
-15.7% YoY
|
-312.92M
-316.81M – -309.03M
-23.3% YoY
|
-500.33M
-573.87M – -418.76M
-59.9% YoY
|
-634.53M
-727.79M – -531.08M
-26.8% YoY
|
| Net Income |
-97.17M
est: -724.4K (-13,312.6%)
|
-143.55M
est: -212.30M (+32.4%)
|
-269.11M
est: -257.51M (-4.5%)
|
-233.66M
est: -222.26M (-5.1%)
|
-209.25M
est: -139.10M (-50.4%)
|
-51.75M
est: -63.76M (+18.8%)
|
-22.68M
est: -22.64M (-0.2%)
|
-9.22M
-22.31M – 3.88M
+59.3% YoY
|
57.40M
51.02M – 63.78M
+722.9% YoY
|
93.84M
-162.58M – 321.55M
+63.5% YoY
|
243.20M
191.66M – 289.67M
+159.2% YoY
|
347.13M
273.56M – 413.46M
+42.7% YoY
|
| SGA |
65.85M
est: 74.08M (-11.1%)
|
199.62M
est: 188.35M (+6.0%)
|
184.99M
est: 99.54M (+85.8%)
|
109.08M
est: 98.80M (+10.4%)
|
142.52M
est: 329.48M (-56.7%)
|
163.07M
est: 385.20M (-57.7%)
|
165.79M
est: 477.10M (-65.3%)
|
459.97M
423.92M – 505.35M
-3.6% YoY
|
532.37M
468.96M – 576.40M
+15.7% YoY
|
656.18M
648.02M – 664.34M
+23.3% YoY
|
1.05B
878.10M – 1.20B
+59.9% YoY
|
1.33B
1.11B – 1.53B
+26.8% YoY
|
| EPS |
-4.02
est: -3.99 (-0.7%)
|
-6.05
est: -5.10 (-18.6%)
|
-11.03
est: -10.05 (-9.8%)
|
-4.33
est: -3.62 (-19.5%)
|
-2.03
est: -0.68 (-200.2%)
|
-0.28
est: -0.32 (+11.9%)
|
-0.11
est: -0.09 (-26.2%)
|
-0.02
-0.11 – 0.02
+73.2% YoY
|
0.27
0.25 – 0.31
+1,257.2% YoY
|
0.55
-0.78 – 1.55
+102.8% YoY
|
1.17
0.92 – 1.39
+113.7% YoY
|
1.67
1.32 – 1.99
+42.7% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | Needham | Buy | Hold | Downgrade |
| 2026-05-01 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-15.03M
OE per share TTM
-0.12
Owner's Yield
-1.90%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
48
Total invested
68.52M
Insider transactions (90d)
0
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 14.27M | 7.30% | — | — | 14.27M | — | HC | Delaware | 2024-11-08 | ↗ |
| 2 | Company, L.P. | 10.00M | 8.06% | — | 10.00M | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 3 | Deerfield Mgmt, L.P. | 10.00M | 8.06% | — | 10.00M | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 4 | Deerfield Partners, L.P. | 10.00M | 8.06% | — | 10.00M | — | — | PN | Delaware | 2022-02-11 | ↗ |
| 5 | James E. Flynn | 10.00M | 8.06% | — | 10.00M | — | — | IN | United States | 2022-02-11 | ↗ |
| 6 | Sina Toussi | 7.92M | 7.40% | 7.92M | — | 7.92M | — | HC, IN | United States | 2023-10-05 | ↗ |
| 7 | Two Seas Capital GP LLC | 7.92M | 7.40% | 7.92M | — | 7.92M | — | HC, OO | Delaware | 2023-10-05 | ↗ |
| 8 | Two Seas Capital LP | 7.92M | 7.40% | 7.92M | — | 7.92M | — | IA, PN | Delaware | 2023-10-05 | ↗ |
| 9 | CVI Investments, Inc. | 6.72M | 9.90% | — | 6.72M | — | 6.72M | CO | Cayman Islands | 2022-02-14 | ↗ |
| 10 | Heights Capital Management, Inc. | 6.72M | 9.90% | — | 6.72M | — | 6.72M | CO | Delaware | 2022-02-14 | ↗ |
| 11 | David Kroin | 6.35M | 9.99% | — | 6.35M | — | — | HC, IN | United States | 2021-12-09 | ↗ |
| 12 | Deep Track Biotechnology Master Fund, Ltd. | 6.35M | 9.99% | — | 6.35M | — | — | CO | Cayman Islands | 2021-12-09 | ↗ |
| 13 | Deep Track Capital, LP | 6.35M | 9.99% | — | 6.35M | — | — | IA, OO | Delaware | 2021-12-09 | ↗ |
| 14 | NAME OF REPORTING PERSONS | 5.71M | 9.00% | — | 5.71M | — | 5.71M | — | Cayman Islands | 2021-12-09 | ↗ |
| 15 | Steven A. Cohen | 4.53M | 5.00% | — | 4.53M | — | — | IN | United States | 2023-04-05 | ↗ |
| 16 | Point72 Asset Management, L.P. | 4.31M | 4.80% | — | 4.31M | — | — | PN | Delaware | 2023-04-05 | ↗ |
| 17 | Point72 Capital Advisors, Inc. | 4.31M | 4.80% | — | 4.31M | — | — | CO | Delaware | 2023-04-05 | ↗ |
| 18 | Israel A. Englander | 3.40M | 1.70% | — | 3.40M | — | 3.40M | IN | Delaware | 2024-10-17 | ↗ |
| 19 | Millennium Group Management LLC | 3.40M | 1.70% | — | 3.40M | — | 3.40M | OO | Delaware | 2024-10-17 | ↗ |
| 20 | Millennium Management LLC | 3.40M | 1.70% | — | 3.40M | — | 3.40M | OO | Delaware | 2024-10-17 | ↗ |
| 21 | STATE STREET CORPORATION | 1.05M | 1.69% | — | 1.01M | — | 1.05M | HC | — | 2022-02-09 | ↗ |
| 22 | Cubist Systematic Strategies, LLC | 219.5K | 0.20% | — | 219.5K | — | — | OO | Delaware | 2023-04-05 | ↗ |
| 23 | Point72 Hong Kong Limited | 1.2K | 4.00% | — | 1.2K | — | 1.2K | OO | Citizenship or place of organization Hong Kong | 2022-08-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
48
-164 vs prev Q
New positions
7
Closed positions
160
Increased
20
Reduced
8
Put/Call ratio
0.00
Calls held
4.4K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NVERSES CAPITAL, LLC | 67.5K +67.5K (+100.0%) | 249.57M +249.6M (+100.0%) | 0.03% +0.034 pp | 0.56% +0.559 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 17.68M +2.8M (+19.2%) | 65.42M +26.1M (+66.4%) | 8.92% +1.388 pp | 0.00% +0.000 pp | USD1.98 +86.9% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 14.95M +2.9M (+23.6%) | 55.30M +23.3M (+72.6%) | 7.54% +1.399 pp | 0.00% +0.000 pp | USD7.66 -51.7% | 50 qtrs — |
| 4 | TWO SEAS CAPITAL LP | 11.90M +2.2M (+22.1%) | 44.04M +18.2M (+70.5%) | 6.01% +1.054 pp | 0.91% +0.493 pp | USD1.76 +110.2% | 11 qtrs — |
| 5 | WASATCH ADVISORS LP | 9.45M +2.4M (+33.8%) | 34.95M +16.2M (+86.8%) | 4.77% +1.179 pp | 0.21% +0.107 pp | USD4.34 -14.7% | 51 qtrs — |
| 6 | D. E. SHAW & CO., INC. | 6.90M +6.7M (+3,208.9%) | 25.54M +25.0M (+4,520.0%) | 3.48% +3.378 pp | 0.01% +0.014 pp | USD3.67 +0.8% | 9 qtrs — |
| 7 | ORBIMED ADVISORS LLC | 5.97M +6.0M (+100.0%) | 22.07M +22.1M (+100.0%) | 3.01% +3.011 pp | 0.45% +0.452 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 8 | STATE STREET CORP | 5.93M +1.5M (+32.4%) | 21.94M +10.1M (+84.9%) | 2.99% +0.717 pp | 0.00% +0.000 pp | USD3.22 +14.9% | 50 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 5.74M +986.3K (+20.8%) | 21.23M +8.6M (+68.6%) | 2.90% +0.482 pp | 0.00% +0.001 pp | USD4.26 -13.1% | 50 qtrs — |
| 10 | MARSHALL WACE, LLP | 5.47M +3.0M (+117.0%) | 20.24M +13.6M (+203.0%) | 2.76% +1.480 pp | 0.02% +0.012 pp | USD2.59 +42.9% | 15 qtrs — |
| 11 | TWO SIGMA INVESTMENTS, LP | 4.74M +2.5M (+111.8%) | 17.55M +11.6M (+195.8%) | 2.39% +1.256 pp | 0.02% +0.016 pp | USD3.57 +3.6% | 17 qtrs — |
| 12 | PENDERFUND CAPITAL MANAGEMENT LTD. | 4.39M -2.3M (-34.2%) | 16.25M -1.4M (-8.2%) | 2.22% -1.175 pp | 2.56% -0.425 pp | USD1.12 +230.4% | 4 qtrs — |
| 13 | AIGH CAPITAL MANAGEMENT LLC | 4.00M +1.0M (+33.3%) | 14.80M +6.9M (+86.2%) | 2.02% +0.495 pp | 3.58% +1.342 pp | USD2.91 +27.1% | 2 qtrs — |
| 14 | MILLENNIUM MANAGEMENT LLC | 3.93M +3.0M (+303.4%) | 14.55M +12.0M (+463.2%) | 1.98% +1.489 pp | 0.01% +0.005 pp | USD3.47 +6.6% | 41 qtrs — |
| 15 | EVERSEPT PARTNERS, LP | 3.85M +3.9M (+100.0%) | 14.25M +14.2M (+100.0%) | 1.94% +1.944 pp | 0.72% +0.718 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 16 | NUVEEN, LLC | 3.61M -99.0K (-2.7%) | 13.36M +3.5M (+35.9%) | 1.82% -0.062 pp | 0.00% +0.001 pp | USD2.51 +47.4% | 4 qtrs — |
| 17 | ROYCE & ASSOCIATES LP | 3.60M +1.3M (+57.0%) | 13.33M +7.2M (+119.3%) | 1.82% +0.652 pp | 0.14% +0.075 pp | USD3.03 +22.1% | 2 qtrs — |
| 18 | MORGAN STANLEY | 3.51M -541.4K (-13.3%) | 13.00M +2.3M (+21.0%) | 1.77% -0.287 pp | 0.00% +0.000 pp | USD2.64 +40.2% | 50 qtrs — |
| 19 | TWO SIGMA ADVISERS, LP | 3.51M +1.6M (+83.7%) | 12.97M +7.9M (+156.5%) | 1.77% +0.800 pp | 0.03% +0.015 pp | USD3.35 +10.4% | 15 qtrs — |
| 20 | GOLDMAN SACHS GROUP INC | 2.85M +1.1M (+66.7%) | 10.54M +6.0M (+132.7%) | 1.44% +0.569 pp | 0.00% +0.001 pp | USD3.02 +22.5% | 45 qtrs — |
| 21 | RENAISSANCE TECHNOLOGIES LLC | 2.19M +1.4M (+183.6%) | 8.12M +6.1M (+295.9%) | 1.11% +0.714 pp | 0.01% +0.010 pp | USD3.11 +19.0% | 11 qtrs — |
| 22 | CAPTION MANAGEMENT, LLC | 2.14M +2.1M (+100.0%) | 7.93M +7.9M (+100.0%) | 1.08% +1.081 pp | 0.05% +0.054 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 23 | JONES FINANCIAL COMPANIES LLLP | 2.09M +2.1M (+167,721.5%) | 7.75M +7.7M (+234,230.9%) | 1.06% +1.056 pp | 0.00% +0.005 pp | USD3.70 +0.0% | 4 qtrs — |
| 24 | NORTHERN TRUST CORP | 2.00M +147.3K (+8.0%) | 7.38M +2.5M (+50.7%) | 1.01% +0.068 pp | 0.00% +0.000 pp | USD3.04 +21.7% | 50 qtrs — |
| 25 | WALLEYE CAPITAL LLC | 1.57M +1.3M (+391.6%) | 5.81M +5.0M (+586.4%) | 0.79% +0.630 pp | 0.02% +0.015 pp | USD3.49 +6.0% | 2 qtrs — |
| 26 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 1.21M +1.2M (+100.0%) | 4.48M +4.5M (+100.0%) | 0.61% +0.611 pp | 2.60% +2.597 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 27 | VOLEON CAPITAL MANAGEMENT LP | 1.15M +946.5K (+455.3%) | 4.27M +3.7M (+675.3%) | 0.58% +0.477 pp | 0.09% +0.078 pp | USD3.51 +5.4% | 2 qtrs — |
| 28 | JANE STREET GROUP, LLC | 1.08M -872.3K (-44.7%) | 4.00M -1.2M (-22.7%) | 0.55% -0.447 pp | 0.00% 0.000 pp | USD2.26 +63.7% | 26 qtrs — |
| 29 | DEUTSCHE BANK AG\ | 1.07M +953.8K (+805.4%) | 3.97M +3.7M (+1,164.2%) | 0.54% +0.481 pp | 0.00% +0.001 pp | USD3.55 +4.2% | 7 qtrs — |
| 30 | JPMORGAN CHASE & CO | 965.1K +19.6K (+2.1%) | 3.57M +1.1M (+42.5%) | 0.49% +0.007 pp | 0.00% +0.000 pp | USD2.23 +65.9% | 44 qtrs — |
| 31 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 935.9K -18.5K (-1.9%) | 3.46M +933.6K (+36.9%) | 0.47% -0.013 pp | 0.00% +0.000 pp | USD2.33 +58.8% | 28 qtrs — |
| 32 | INVESCO LTD. | 765.1K +145.4K (+23.5%) | 2.83M +1.2M (+72.4%) | 0.39% +0.071 pp | 0.00% +0.000 pp | USD2.12 +74.5% | 19 qtrs — |
| 33 | CITADEL ADVISORS LLC | 750.1K -780.3K (-51.0%) | 2.78M -1.3M (-31.6%) | 0.38% -0.399 pp | 0.00% 0.000 pp | USD2.03 +82.3% | 34 qtrs — |
| 34 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 715.3K +128.9K (+22.0%) | 2.65M +1.1M (+70.3%) | 0.36% +0.063 pp | 0.00% +0.000 pp | USD2.37 +56.1% | 45 qtrs — |
| 35 | BANK OF AMERICA CORP /DE/ | 696.8K +392.2K (+128.8%) | 2.58M +1.8M (+219.4%) | 0.35% +0.197 pp | 0.00% +0.000 pp | USD3.23 +14.6% | 50 qtrs — |
| 36 | WELLINGTON MANAGEMENT GROUP LLP | 641.2K -40.1K (-5.9%) | 2.37M +566.9K (+31.4%) | 0.32% -0.023 pp | 0.00% +0.000 pp | USD2.65 +39.6% | 8 qtrs — |
| 37 | VICTORY CAPITAL MANAGEMENT INC | 596.0K +169.1K (+39.6%) | 2.21M +1.1M (+94.9%) | 0.30% +0.084 pp | 0.00% +0.001 pp | USD2.93 +26.3% | 11 qtrs — |
| 38 | BANK OF NEW YORK MELLON CORP | 549.1K +86.0K (+18.6%) | 2.03M +804.5K (+65.6%) | 0.28% +0.042 pp | 0.00% +0.000 pp | USD2.69 +37.5% | 50 qtrs — |
| 39 | BARCLAYS PLC | 443.3K +133.7K (+43.2%) | 1.64M +1.1M (+221.0%) | 0.22% +0.066 pp | 0.00% +0.000 pp | USD2.83 +30.7% | 50 qtrs — |
| 40 | BURKEHILL GLOBAL MANAGEMENT, LP | 400.0K +400.0K (+100.0%) | 1.48M +1.5M (+100.0%) | 0.20% +0.202 pp | 0.10% +0.098 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 41 | SUMMIT WEALTH GROUP, LLC | 340.6K +17.6K (+5.5%) | 1.26M +404.3K (+47.2%) | 0.17% +0.008 pp | 0.29% +0.087 pp | USD1.80 +105.6% | 6 qtrs — |
| 42 | MACKENZIE FINANCIAL CORP | 337.0K +64.0K (+23.5%) | 1.24M +517.7K (+71.6%) | 0.17% +0.031 pp | 0.00% +0.001 pp | USD2.84 +30.3% | 13 qtrs — |
| 43 | UBS GROUP AG | 313.4K -933.0K (-74.9%) | 1.16M -2.1M (-64.9%) | 0.16% -0.475 pp | 0.00% 0.000 pp | USD1.55 +138.7% | 45 qtrs — |
| 44 | AQR CAPITAL MANAGEMENT LLC | 290.5K +5.6K (+2.0%) | 1.07M +319.9K (+42.4%) | 0.15% +0.002 pp | 0.00% +0.000 pp | USD1.76 +110.2% | 6 qtrs — |
| 45 | MARINER, LLC | 278.7K -23.9K (-7.9%) | 1.03M +229.4K (+28.6%) | 0.14% -0.013 pp | 0.00% +0.000 pp | USD2.65 +39.6% | 2 qtrs — |
| 46 | PRINCIPAL FINANCIAL GROUP INC | 276.3K +86.2K (+45.4%) | 1.02M +518.6K (+103.0%) | 0.14% +0.043 pp | 0.00% +0.000 pp | USD1.89 +95.8% | 16 qtrs — |
| 47 | RHUMBLINE ADVISERS | 269.7K -7.8K (-2.8%) | 998.0K +262.7K (+35.7%) | 0.14% -0.005 pp | 0.00% +0.000 pp | USD2.36 +56.8% | 44 qtrs — |
| 48 | WELLS FARGO & COMPANY/MN | 263.2K +117.3K (+80.4%) | 973.8K +587.3K (+151.9%) | 0.13% +0.059 pp | 0.00% +0.000 pp | USD2.59 +42.9% | 50 qtrs — |
| 49 | ALLIANCEBERNSTEIN L.P. | 261.8K +50.0K (+23.6%) | 968.5K +407.3K (+72.6%) | 0.13% +0.025 pp | 0.00% +0.000 pp | USD2.13 +73.7% | 7 qtrs — |
| 50 | QUADRATURE CAPITAL LTD | 259.6K +259.6K (+100.0%) | 960.4K +960.4K (+100.0%) | 0.13% +0.131 pp | 0.01% +0.010 pp | USD3.70 +0.0% | 4 qtrs — |
| 51 | QUANTBOT TECHNOLOGIES LP | 244.3K +64.7K (+36.0%) | 903.9K +427.8K (+89.9%) | 0.12% +0.032 pp | 0.03% +0.017 pp | USD2.93 +26.3% | 2 qtrs — |
| 52 | HRT FINANCIAL LP | 239.4K +81.5K (+51.6%) | 885.0K +467.0K (+111.7%) | 0.12% +0.041 pp | 0.00% +0.001 pp | USD3.01 +22.9% | 5 qtrs — |
| 53 | HEADLANDS TECHNOLOGIES LLC | 221.1K +124.8K (+129.7%) | 818.0K +562.9K (+220.7%) | 0.11% +0.063 pp | 0.07% +0.048 pp | USD3.24 +14.2% | 11 qtrs — |
| 54 | BNP PARIBAS ARBITRAGE, SNC | 213.7K -143.7K (-40.2%) | 790.6K -156.4K (-16.5%) | 0.11% -0.074 pp | 0.00% 0.000 pp | USD2.60 +42.3% | 49 qtrs — |
| 55 | PRICE T ROWE ASSOCIATES INC /MD/ | 188.6K +35.7K (+23.4%) | 698.0K +292.0K (+71.9%) | 0.10% +0.018 pp | 0.00% +0.000 pp | USD2.64 +40.2% | 44 qtrs — |
| 56 | VIRTUS INVESTMENT ADVISERS, INC. | 177.5K +177.5K (+100.0%) | 656.8K +656.8K (+100.0%) | 0.09% +0.090 pp | 0.18% +0.179 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 57 | UMB BANK, N.A. | 170.0K +— (+0.0%) | 629.0K +178.5K (+39.6%) | 0.09% -0.001 pp | 0.01% +0.002 pp | USD0.98 +277.6% | 3 qtrs — |
| 58 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 169.0K -94.2K (-35.8%) | 625.4K -72.3K (-10.4%) | 0.09% -0.048 pp | 0.01% +0.004 pp | USD2.21 +67.4% | 4 qtrs — |
| 59 | DIAMETRIC CAPITAL, LP | 169.0K -67.1K (-28.4%) | 625.3K -462.0 (-0.1%) | 0.09% -0.035 pp | 0.17% -0.065 pp | USD1.78 +107.9% | 9 qtrs — |
| 60 | XTX TOPCO LTD | 162.0K +162.0K (+100.0%) | 599.3K +599.3K (+100.0%) | 0.08% +0.082 pp | 0.02% +0.016 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 61 | GRAHAM CAPITAL MANAGEMENT, L.P. | 161.6K +146.4K (+968.9%) | 597.8K +557.7K (+1,392.5%) | 0.08% +0.074 pp | 0.01% +0.014 pp | USD3.60 +2.8% | 13 qtrs — |
| 62 | METLIFE INVESTMENT MANAGEMENT, LLC | 129.7K +23.3K (+21.8%) | 480.0K +197.9K (+70.1%) | 0.07% +0.011 pp | 0.00% +0.001 pp | USD2.06 +79.6% | 7 qtrs — |
| 63 | WOODLINE PARTNERS LP | 127.0K -255.1K (-66.8%) | 470.0K -542.5K (-53.6%) | 0.06% -0.130 pp | 0.00% -0.003 pp | USD2.80 +32.1% | 9 qtrs — |
| 64 | CITIGROUP INC | 121.1K +64.0K (+112.0%) | 448.0K +296.7K (+196.0%) | 0.06% +0.032 pp | 0.00% +0.000 pp | USD2.94 +25.9% | 50 qtrs — |
| 65 | CREATIVE PLANNING | 117.4K +67.5K (+135.1%) | 434.3K +302.0K (+228.3%) | 0.06% +0.034 pp | 0.00% +0.000 pp | USD3.25 +13.8% | 2 qtrs — |
| 66 | POLEN CAPITAL MANAGEMENT LLC | 116.3K +116.3K (+100.0%) | 430.3K +430.3K (+100.0%) | 0.06% +0.059 pp | 0.00% +0.002 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 67 | HIGHTOWER ADVISORS, LLC | 113.9K -6.1K (-5.1%) | 421.4K +103.4K (+32.5%) | 0.06% -0.004 pp | 0.00% +0.000 pp | USD2.39 +54.8% | 11 qtrs — |
| 68 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 108.6K +14.9K (+15.8%) | 401.9K +153.4K (+61.7%) | 0.05% +0.007 pp | 0.00% +0.000 pp | USD1.94 +90.7% | 6 qtrs — |
| 69 | SUMMIT FINANCIAL, LLC | 107.3K +8.6K (+8.7%) | 396.9K +135.5K (+51.8%) | 0.05% +0.004 pp | 0.01% +0.002 pp | USD2.10 +76.2% | 10 qtrs — |
| 70 | TOCQUEVILLE ASSET MANAGEMENT L.P. | 107.0K +16.0K (+17.6%) | 395.9K +154.8K (+64.2%) | 0.05% +0.008 pp | 0.01% +0.002 pp | USD2.76 +34.1% | 8 qtrs — |
| 71 | PARALLEL ADVISORS, LLC | 106.7K -10.7K (-9.1%) | 394.7K +83.6K (+26.9%) | 0.05% -0.006 pp | 0.01% +0.002 pp | USD0.99 +273.7% | 12 qtrs — |
| 72 | INTECH INVESTMENT MANAGEMENT LLC | 104.9K +5.4K (+5.5%) | 388.3K +124.6K (+47.3%) | 0.05% +0.002 pp | 0.00% +0.001 pp | USD1.69 +118.9% | 6 qtrs — |
| 73 | ROUND ROCK ADVISORS, LLC | 101.6K +101.6K (+100.0%) | 375.7K +375.7K (+100.0%) | 0.05% +0.051 pp | 0.06% +0.057 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 74 | ADVENT CAPITAL MANAGEMENT /DE/ | 100.0K +100.0K (+100.0%) | 370.0K +370.0K (+100.0%) | 0.05% +0.051 pp | 0.01% +0.007 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 75 | WALLEYE TRADING LLC | 93.2K +93.2K (+100.0%) | 344.8K +344.8K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.001 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 76 | ADVISOR GROUP HOLDINGS, INC. | 86.4K +5.0K (+6.2%) | 319.8K +124.6K (+63.8%) | 0.04% +0.002 pp | 0.00% +0.000 pp | USD5.79 -36.1% | 24 qtrs — |
| 77 | FMR LLC | 80.4K +17.1K (+27.0%) | 297.5K +129.7K (+77.3%) | 0.04% +0.008 pp | 0.00% +0.000 pp | USD2.96 +25.0% | 16 qtrs — |
| 78 | RAYMOND JAMES FINANCIAL INC | 76.2K +16.1K (+26.8%) | 282.0K +122.8K (+77.1%) | 0.04% +0.008 pp | 0.00% +0.000 pp | USD2.63 +40.7% | 5 qtrs — |
| 79 | SEI INVESTMENTS CO | 76.0K -1.8K (-2.3%) | 281.2K +75.1K (+36.5%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD2.65 +39.6% | 6 qtrs — |
| 80 | SCHONFELD STRATEGIC ADVISORS LLC | 75.2K +75.2K (+100.0%) | 278.4K +278.4K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.001 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 81 | INTEGRATED QUANTITATIVE INVESTMENTS LLC | 72.2K +72.2K (+100.0%) | 267.3K +267.3K (+100.0%) | 0.04% +0.037 pp | 0.06% +0.057 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 82 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 70.0K +235.0 (+0.3%) | 259.1K +74.2K (+40.1%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD2.25 +64.4% | 7 qtrs — |
| 83 | PROFUND ADVISORS LLC | 69.7K +27.5K (+65.2%) | 257.9K +146.1K (+130.7%) | 0.04% +0.014 pp | 0.01% +0.004 pp | USD3.06 +20.9% | 5 qtrs — |
| 84 | CAPITAL ADVISORS WEALTH MANAGEMENT, LLC | 67.6K +25.0K (+58.7%) | 250.0K +137.2K (+121.6%) | 0.03% +0.013 pp | 0.03% +0.018 pp | USD2.83 +30.7% | 8 qtrs — |
| 85 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 66.9K +66.9K (+100.0%) | 247.5K +247.5K (+100.0%) | 0.03% +0.034 pp | 0.01% +0.007 pp | USD3.70 +0.0% | 1 qtrs NEW |
| 86 | NEW YORK STATE COMMON RETIREMENT FUND | 63.9K +32.5K (+103.5%) | 236.4K +153.2K (+184.1%) | 0.03% +0.016 pp | 0.00% +0.000 pp | USD3.03 +22.1% | 7 qtrs — |
| 87 | STATE OF WYOMING | 63.4K +63.4K (+100.0%) | 234.4K +234.4K (+100.0%) | 0.03% +0.032 pp | 0.03% +0.026 pp | USD3.70 +0.0% | 7 qtrs — |
| 88 | RAFFERTY ASSET MANAGEMENT, LLC | 61.0K +32.8K (+116.1%) | 225.9K +151.0K (+201.7%) | 0.03% +0.017 pp | 0.00% +0.001 pp | USD3.21 +15.3% | 5 qtrs — |
| 89 | PINNACLE ASSOCIATES LTD | 60.6K -524.0 (-0.9%) | 224.2K +62.2K (+38.4%) | 0.03% -0.001 pp | 0.00% +0.001 pp | USD30.28 -87.8% | 37 qtrs — |
| 90 | LOS ANGELES CAPITAL MANAGEMENT LLC | 67.8K +19.6K (+40.6%) | 192.4K +64.8K (+50.7%) | 0.03% +0.010 pp | 0.00% +0.000 pp | USD2.09 +77.0% | 4 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 29 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.47% | 6.94M | 0.35% |
| 2 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.31% | 71.3K | 1.22% |
| 3 | Fidelity Enhanced Small Cap ETF FESM | 0.23% | 13.53M | 0.28% |
| 4 | Vanguard U.S. Momentum Factor ETF VFMO | 0.09% | 1.56M | 0.13% |
| 5 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.06% | 43.1K | 0.35% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.06% | 644.3K | 0.35% |
| 7 | Vanguard Global Momentum Factor ETF VMO.TO | 0.06% | 206.0K | 0.38% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.06% | 260.4K | 0.40% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.06% | 42.1K | 0.19% |
| 10 | Invesco RAFI US 1500 Small-Mid ETF PRFZ | 0.04% | 1.17M | 0.34% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.50
Neutral
Ratio by volume
3.00
Bullish
Buys
6
Sells
4
Shares acquired
2.41M
Shares disposed
39.4K
Cash buys
—
Cash sales
4.00
Net activity
+2,370,591
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | Looker Benjamin | Officer | S-Sale | D | Common Stock | 5,708 | 2.70 | 15.4K | 679,348 | D | ↗ |
| 2026-03-17 | Koenig Sheldon L. | Director / Officer | S-Sale | D | Common Stock | 25,578 | 2.72 | 69.5K | 2,172,699 | D | ↗ |
| 2026-03-17 | Halladay Benjamin | Officer | S-Sale | D | Common Stock | 6,424 | 2.71 | 17.4K | 713,602 | D | ↗ |
| 2026-03-13 | Looker Benjamin | Officer | A-Award | A | Common Stock | 300,840 | 0.00 | — | 685,056 | D | ↗ |
| 2026-03-13 | Koenig Sheldon L. | Director / Officer | A-Award | A | Common Stock | 723,760 | 0.00 | — | 2,198,277 | D | ↗ |
| 2026-03-13 | Halladay Benjamin | Officer | A-Award | A | Stock Option (right to buy) | 221,270 | 2.44 | 539.9K | 221,270 | D | ↗ |
| 2026-01-20 | Looker Benjamin | Officer | S-Sale | D | Common Stock | 1,689 | 2.88 | 4.9K | 384,216 | D | ↗ |
| 2025-12-17 | Looker Benjamin | Officer | S-Sale | D | Common Stock | 6,517 | 3.67 | 23.9K | 385,905 | D | ↗ |
| 2025-12-17 | Koenig Sheldon L. | Director / Officer | S-Sale | D | Common Stock | 48,244 | 3.67 | 177.2K | 1,470,587 | D | ↗ |
| 2025-12-17 | Halladay Benjamin | Officer | S-Sale | D | Common Stock | 7,337 | 3.67 | 26.9K | 467,525 | D | ↗ |
| 2025-12-04 | Harlow John B. Jr. | Officer | A-Award | A | Common Stock | 424,536 | 0.00 | — | 424,536 | D | ↗ |
| 2025-11-17 | Harlow John B. Jr. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-09-17 | Looker Benjamin | Officer | S-Sale | D | Common Stock | 6,267 | 2.80 | 17.6K | 393,670 | D | ↗ |
| 2025-09-17 | Koenig Sheldon L. | Director / Officer | S-Sale | D | Common Stock | 28,427 | 2.79 | 79.3K | 1,518,831 | D | ↗ |
| 2025-09-17 | Halladay Benjamin | Officer | S-Sale | D | Common Stock | 7,046 | 2.81 | 19.8K | 474,862 | D | ↗ |
| 2025-07-17 | Looker Benjamin | Officer | S-Sale | D | Common Stock | 1,304 | 1.13 | 1.5K | 399,937 | D | ↗ |
| 2025-07-17 | Halladay Benjamin | Officer | S-Sale | D | Common Stock | 11 | 1.12 | 12.27 | 474,462 | D | ↗ |
| 2025-07-01 | THOMPSON JOHN CRAIG | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-17 | Looker Benjamin | Officer | S-Sale | D | Common Stock | 6,422 | 1.15 | 7.4K | 401,241 | D | ↗ |
| 2025-06-17 | Koenig Sheldon L. | Director / Officer | S-Sale | D | Common Stock | 30,474 | 1.11 | 33.8K | 1,541,488 | D | ↗ |
| 2025-06-17 | Halladay Benjamin | Officer | S-Sale | D | Common Stock | 7,229 | 1.15 | 8.3K | 474,473 | D | ↗ |
| 2025-05-29 | Woody Tracy M | Director | A-Award | A | Stock Option (right to buy) | 88,000 | 0.87 | 76.6K | 88,000 | D | ↗ |
| 2025-05-29 | VITULLO NICOLE | Director | A-Award | A | Stock Option (right to buy) | 88,000 | 0.87 | 76.6K | 88,000 | D | ↗ |
| 2025-05-29 | Shepard Jay | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 0.87 | 38.3K | 44,000 | D | ↗ |
| 2025-05-29 | ROCAMBOLI STEPHEN | Director | A-Award | A | Common Stock | 33,000 | 0.00 | — | 69,261 | D | ↗ |
| 2025-05-29 | Hoffman Robert E. | Director | A-Award | A | Common Stock | 5,280 | 0.00 | — | 5,280 | D | ↗ |
| 2025-05-29 | Fischer Seth H. Z. | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 0.87 | 38.3K | 44,000 | D | ↗ |
| 2025-05-29 | CARROLL J MARTIN | Director | A-Award | A | Stock Option (right to buy) | 44,000 | 0.87 | 38.3K | 44,000 | D | ↗ |
| 2025-04-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 108 | 0.98 | 105.62 | 370,218 | D | ↗ |
| 2025-04-17 | Halladay Benjamin | Officer | S-Sale | D | Common Stock | 8 | 0.96 | 7.71 | 481,702 | D | ↗ |
| 2025-04-01 | Hoffman Robert E. | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 1.41 | 56.4K | 40,000 | D | ↗ |
| 2025-03-18 | Warren Eric | Officer | S-Sale | D | Common Stock | 2,433 | 1.49 | 3.6K | 370,326 | D | ↗ |
| 2025-03-18 | Koenig Sheldon L. | Director / Officer | S-Sale | D | Common Stock | 13,047 | 1.50 | 19.6K | 1,571,962 | D | ↗ |
| 2025-03-18 | Halladay Benjamin | Officer | S-Sale | D | Common Stock | 3,535 | 1.48 | 5.2K | 481,710 | D | ↗ |
| 2025-03-14 | Warren Eric | Officer | A-Award | A | Common Stock | 213,000 | 0.00 | — | 372,759 | D | ↗ |
| 2025-03-14 | Looker Benjamin | Officer | A-Award | A | Common Stock | 224,000 | 0.00 | — | 407,663 | D | ↗ |
| 2025-03-14 | Koenig Sheldon L. | Director / Officer | A-Award | A | Common Stock | 840,000 | 0.00 | — | 1,585,009 | D | ↗ |
| 2025-03-14 | Halladay Benjamin | Officer | A-Award | A | Common Stock | 238,000 | 0.00 | — | 485,245 | D | ↗ |
| 2025-02-19 | Warren Eric | Officer | S-Sale | D | Common Stock | 239 | 1.87 | 446.45 | 159,759 | D | ↗ |
| 2025-02-19 | Halladay Benjamin | Officer | S-Sale | D | Common Stock | 11 | 1.86 | 20.46 | 240,671 | D | ↗ |
| 2025-01-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 123 | 2.26 | 277.98 | 159,998 | D | ↗ |
| 2025-01-17 | Halladay Benjamin | Officer | S-Sale | D | Common Stock | 9 | 2.27 | 20.39 | 240,682 | D | ↗ |
| 2024-12-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 2,234 | 2.43 | 5.4K | 160,121 | D | ↗ |
| 2024-12-17 | Koenig Sheldon L. | Director / Officer | S-Sale | D | Common Stock | 12,447 | 2.47 | 30.7K | 739,819 | D | ↗ |
| 2024-12-17 | Halladay Benjamin | Officer | S-Sale | D | Common Stock | 3,245 | 2.42 | 7.9K | 240,691 | D | ↗ |
| 2024-11-19 | Warren Eric | Officer | S-Sale | D | Common Stock | 197 | 2.17 | 426.51 | 162,355 | D | ↗ |
| 2024-10-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 107 | 2.12 | 226.73 | 162,552 | D | ↗ |
| 2024-09-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 2,608 | 1.78 | 4.7K | 162,659 | — | ↗ |
| 2024-09-17 | Koenig Sheldon L. | Director / Officer | S-Sale | D | Common Stock | 14,550 | 1.80 | 26.1K | 752,266 | — | ↗ |
| 2024-08-19 | Warren Eric | Officer | S-Sale | D | Common Stock | 211 | 1.95 | 410.61 | 165,267 | — | ↗ |
| 2024-07-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 108 | 2.59 | 279.40 | 165,478 | — | ↗ |
| 2024-07-17 | Foody Joanne M. | Officer | S-Sale | D | Common Stock | 917 | 2.60 | 2.4K | 272,862 | — | ↗ |
| 2024-06-18 | Warren Eric | Officer | S-Sale | D | Common Stock | 2,540 | 2.86 | 7.3K | 165,586 | — | ↗ |
| 2024-06-18 | Foody Joanne M. | Officer | S-Sale | D | Common Stock | 3,285 | 2.87 | 9.4K | 273,779 | — | ↗ |
| 2024-05-23 | Woody Tracy M | Director | A-Award | A | Stock Option (right to buy) | 65,000 | 2.25 | 146.3K | 65,000 | — | ↗ |
| 2024-05-23 | VITULLO NICOLE | Director | A-Award | A | Stock Option (right to buy) | 65,000 | 2.25 | 146.3K | 65,000 | — | ↗ |
| 2024-05-23 | Shepard Jay | Director | A-Award | A | Stock Option (right to buy) | 32,500 | 2.25 | 73.1K | 32,500 | — | ↗ |
| 2024-05-23 | ROCAMBOLI STEPHEN | Director | A-Award | A | Stock Option (right to buy) | 32,500 | 2.25 | 73.1K | 32,500 | — | ↗ |
| 2024-05-23 | GOTTO ANTONIO M JR MD D PHIL | Director | A-Award | A | Common Stock | 23,000 | 0.00 | — | 51,599 | — | ↗ |
| 2024-05-23 | Fuhrman Alan | Director | A-Award | A | Stock Option (right to buy) | 32,500 | 2.25 | 73.1K | 32,500 | — | ↗ |
| 2024-05-23 | Fischer Seth H. Z. | Director | A-Award | A | Common Stock | 23,000 | 0.00 | — | 28,150 | — | ↗ |
| 2024-05-23 | CARROLL J MARTIN | Director | A-Award | A | Stock Option (right to buy) | 32,500 | 2.25 | 73.1K | 32,500 | — | ↗ |
| 2024-05-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 192 | 2.48 | 476.74 | 168,126 | — | ↗ |
| 2024-03-14 | Warren Eric | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 2.05 | 307.5K | 150,000 | — | ↗ |
| 2024-03-14 | Looker Benjamin | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 2.05 | 307.5K | 150,000 | — | ↗ |
| 2024-03-14 | Koenig Sheldon L. | Director / Officer | A-Award | A | Common Stock | 454,000 | 0.00 | — | 766,816 | — | ↗ |
| 2024-03-14 | Halladay Benjamin | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 2.05 | 410.0K | 200,000 | — | ↗ |
| 2024-03-14 | Foody Joanne M. | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 2.05 | 410.0K | 200,000 | — | ↗ |
| 2023-09-20 | Warren Eric | Officer | S-Sale | D | Common Stock | 742 | 1.25 | 923.79 | 68,318 | — | ↗ |
| 2023-08-18 | Warren Eric | Officer | S-Sale | D | Common Stock | 243 | 1.41 | 343.60 | 69,060 | — | ↗ |
| 2023-08-08 | Foody Joanne M. | Officer | A-Award | A | Stock Option (right to buy | 44,650 | 1.62 | 72.3K | 44,650 | — | ↗ |
| 2023-07-19 | Warren Eric | Officer | S-Sale | D | Common Stock | 106 | 1.59 | 168.01 | 69,303 | — | ↗ |
| 2023-06-21 | Warren Eric | Officer | S-Sale | D | Common Stock | 603 | 1.48 | 894.25 | 69,409 | — | ↗ |
| 2023-06-15 | Woody Tracy M | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 1.37 | 28.8K | 21,000 | — | ↗ |
| 2023-06-15 | VITULLO NICOLE | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 1.37 | 28.8K | 21,000 | — | ↗ |
| 2023-06-15 | Shepard Jay | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 1.37 | 28.8K | 21,000 | — | ↗ |
| 2023-06-15 | ROCAMBOLI STEPHEN | Director | A-Award | A | Common Stock | 5,150 | 0.00 | — | 13,261 | — | ↗ |
| 2023-06-15 | GOTTO ANTONIO M JR MD D PHIL | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 1.37 | 28.8K | 21,000 | — | ↗ |
| 2023-06-15 | Fuhrman Alan | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 1.37 | 28.8K | 21,000 | — | ↗ |
| 2023-06-15 | Fischer Seth H. Z. | Director | A-Award | A | Common Stock | 5,150 | 0.00 | — | 5,150 | — | ↗ |
| 2023-06-15 | CARROLL J MARTIN | Director | A-Award | A | Stock Option (right to buy) | 21,000 | 1.37 | 28.8K | 21,000 | — | ↗ |
| 2023-05-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 219 | 1.62 | 355.66 | 70,012 | — | ↗ |
| 2023-05-11 | CARROLL J MARTIN | Director | P-Purchase | A | Common Stock | 23,091 | 1.57 | 36.3K | 36,500 | — | ↗ |
| 2023-05-10 | ROCAMBOLI STEPHEN | Director | P-Purchase | A | Common Stock | 8,111 | 1.50 | 12.1K | 8,111 | — | ↗ |
| 2023-05-10 | CARROLL J MARTIN | Director | P-Purchase | A | Common Stock | 8,409 | 1.49 | 12.5K | 13,409 | — | ↗ |
| 2023-05-09 | Koenig Sheldon L. | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 1.26 | 25.2K | 312,816 | — | ↗ |
| 2023-04-19 | Warren Eric | Officer | S-Sale | D | Common Stock | 115 | 1.28 | 146.97 | 70,231 | — | ↗ |
| 2023-04-19 | Looker Benjamin | Officer | S-Sale | D | Common Stock | 1,290 | 1.27 | 1.6K | 83,663 | — | ↗ |
| 2023-04-19 | Foody Joanne M. | Officer | S-Sale | D | Common Stock | 938 | 1.27 | 1.2K | 127,064 | — | ↗ |
| 2023-03-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 526 | 1.78 | 937.49 | 70,346 | — | ↗ |
| 2023-03-17 | Koenig Sheldon L. | Director / Officer | S-Sale | D | Common Stock | 6,999 | 1.78 | 12.5K | 292,816 | — | ↗ |
| 2023-03-17 | Foody Joanne M. | Officer | S-Sale | D | Common Stock | 3,808 | 1.78 | 6.8K | 128,002 | — | ↗ |
| 2023-03-14 | Warren Eric | Officer | A-Award | A | Common Stock | 22,300 | 0.00 | — | 70,872 | — | ↗ |
| 2023-03-14 | Looker Benjamin | Officer | A-Award | A | Common Stock | 20,500 | 0.00 | — | 84,953 | — | ↗ |
| 2023-03-14 | Koenig Sheldon L. | Director / Officer | A-Award | A | Common Stock | 105,000 | 0.00 | — | 299,815 | — | ↗ |
| 2023-03-14 | Halladay Benjamin | Officer | A-Award | A | Stock Option (right to buy) | 39,000 | 4.02 | 156.8K | 39,000 | — | ↗ |
| 2023-03-14 | Foody Joanne M. | Officer | A-Award | A | Common Stock | 28,750 | 0.00 | — | 131,810 | — | ↗ |
| 2023-03-07 | Warren Eric | Officer | S-Sale | D | Common Stock | 5,090 | 5.06 | 25.7K | 48,572 | — | ↗ |
| 2023-03-07 | Koenig Sheldon L. | Director / Officer | S-Sale | D | Common Stock | 5,441 | 5.06 | 27.5K | 194,815 | — | ↗ |
| 2023-03-07 | Foody Joanne M. | Officer | S-Sale | D | Common Stock | 3,884 | 5.07 | 19.7K | 103,060 | — | ↗ |
| 2023-01-18 | Looker Benjamin | Officer | S-Sale | D | Common Stock | 6,347 | 7.00 | 44.4K | 64,453 | — | ↗ |
| 2023-01-18 | Foody Joanne M. | Officer | S-Sale | D | Common Stock | 1,191 | 6.99 | 8.3K | 106,944 | — | ↗ |
| 2022-12-09 | Halladay Benjamin | Officer | A-Award | A | Stock Option (right to buy) | 66,000 | 0.00 | — | 66,000 | — | ↗ |
| 2022-11-16 | Halladay Benjamin | Officer | — | D | Common Stock | 0 | 0.00 | — | 19,771 | — | ↗ |
| 2022-10-18 | Warren Eric | Officer | S-Sale | D | Common Stock | 107 | 7.69 | 822.83 | 53,662 | — | ↗ |
| 2022-10-18 | Foody Joanne M. | Officer | S-Sale | D | Common Stock | 942 | 7.69 | 7.2K | 108,135 | — | ↗ |
| 2022-09-19 | Warren Eric | Officer | S-Sale | D | Common Stock | 255 | 6.92 | 1.8K | 53,769 | — | ↗ |
| 2022-09-19 | Koenig Sheldon L. | Director / Officer | S-Sale | D | Common Stock | 3,394 | 6.94 | 23.5K | 198,257 | — | ↗ |
| 2022-08-31 | Warren Eric | Officer | P-Purchase | A | Common Stock | 1,000 | 7.46 | 7.5K | 54,024 | — | ↗ |
| 2022-08-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 199 | 6.82 | 1.4K | 53,024 | — | ↗ |
| 2022-08-05 | Koenig Sheldon L. | Officer | P-Purchase | A | Common Stock | 8,606 | 5.80 | 50.0K | 198,771 | — | ↗ |
| 2022-07-19 | Warren Eric | Officer | S-Sale | D | Common Stock | 431 | 6.58 | 2.8K | 53,223 | — | ↗ |
| 2022-07-19 | Foody Joanne M. | Officer | S-Sale | D | Common Stock | 3,901 | 6.55 | 25.6K | 109,077 | — | ↗ |
| 2022-06-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 256 | 4.90 | 1.3K | 53,654 | — | ↗ |
| 2022-06-17 | Koenig Sheldon L. | Officer | S-Sale | D | Common Stock | 4,552 | 4.99 | 22.7K | 190,165 | — | ↗ |
| 2022-06-07 | Warren Eric | Officer | A-Award | A | Stock Option (right to buy) | 52,000 | 0.00 | — | 52,000 | — | ↗ |
| 2022-06-07 | Looker Benjamin | Officer | A-Award | A | Stock Option (right to buy) | 52,000 | 0.00 | — | 52,000 | — | ↗ |
| 2022-06-07 | Koenig Sheldon L. | Director / Officer | A-Award | A | Stock Option (right to buy) | 91,000 | 6.20 | 564.2K | 91,000 | — | ↗ |
| 2022-06-07 | Foody Joanne M. | Officer | A-Award | A | Stock Option (right to buy) | 52,000 | 0.00 | — | 52,000 | — | ↗ |
| 2022-06-02 | CARROLL J MARTIN | Director | P-Purchase | A | Common Stock | 5,000 | 5.64 | 28.2K | 5,000 | — | ↗ |
| 2022-06-01 | CARROLL J MARTIN | Director | A-Award | A | Stock Option (right to buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-05-26 | Woody Tracy M | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-26 | VITULLO NICOLE | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-26 | Shepard Jay | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 5.51 | 110.2K | 20,000 | — | ↗ |
| 2022-05-26 | ROCAMBOLI STEPHEN | Director | A-Award | A | Stock Option (right to buy) | 1,589 | 0.00 | — | 1,589 | — | ↗ |
| 2022-05-26 | GOTTO ANTONIO M JR MD D PHIL | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 5.51 | 110.2K | 20,000 | — | ↗ |
| 2022-05-26 | Fuhrman Alan | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-26 | Fischer Seth H. Z. | Director | A-Award | A | Stock Option (right to buy | 11,561 | 0.00 | — | 11,561 | — | ↗ |
| 2022-05-26 | Berkowitz Jeffrey | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-05-17 | Warren Eric | Officer | S-Sale | D | Common Stock | 196 | 5.98 | 1.2K | 53,910 | — | ↗ |
| 2022-04-28 | ROCAMBOLI STEPHEN | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-17 | Koenig Sheldon L. | Officer | S-Sale | D | Common Stock | 571 | 4.58 | 2.6K | 194,717 | — | ↗ |
| 2022-03-14 | Warren Eric | Officer | A-Award | A | Common Stock | 13,000 | 0.00 | — | 54,106 | — | ↗ |
| 2022-03-14 | Koenig Sheldon L. | Officer | A-Award | A | Common Stock | 116,000 | 0.00 | — | 195,288 | — | ↗ |
| 2022-03-14 | Foody Joanne M. | Officer | A-Award | A | Common Stock | 28,000 | 0.00 | — | 112,978 | — | ↗ |
| 2022-03-14 | Bartram Richard | Officer | A-Award | A | Common Stock | 37,000 | 0.00 | — | 82,751 | — | ↗ |
| 2022-03-01 | Warren Eric | Officer | — | D | Common Stock | 0 | 0.00 | — | 24,000 | — | ↗ |
| 2022-01-27 | Looker Benjamin | Officer | A-Award | A | Stock Option (right to buy) | 100,450 | 3.65 | 366.6K | 100,450 | — | ↗ |
| 2022-01-01 | Looker Benjamin | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-29 | Koenig Sheldon L. | Director / Officer | A-Award | A | Common Stock | 26,700 | 0.00 | — | 76,700 | — | ↗ |
| 2021-10-29 | Foody Joanne M. | Officer | A-Award | A | Common Stock | 22,450 | 0.00 | — | 84,978 | — | ↗ |
| 2021-10-29 | Bartram Richard | Officer | A-Award | A | Common Stock | 18,700 | 0.00 | — | 43,852 | — | ↗ |
| 2021-10-28 | Fischer Seth H. Z. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-28 | Foody Joanne M. | Officer | A-Award | A | Common Stock | 62,528 | 0.00 | — | 62,528 | — | ↗ |
| 2021-06-28 | Bartram Richard | Officer | A-Award | A | Stock Option (right to buy) | 37,500 | 22.52 | 844.5K | 37,500 | — | ↗ |
| 2021-05-27 | Woody Tracy M | Director | A-Award | A | Common Stock | 12,376 | 0.00 | — | 28,416 | — | ↗ |
| 2021-05-27 | VITULLO NICOLE | Director | A-Award | A | Common Stock | 12,376 | 0.00 | — | 31,768 | — | ↗ |
| 2021-05-27 | Shepard Jay | Director | A-Award | A | Common Stock | 12,376 | 0.00 | — | 23,449 | — | ↗ |
| 2021-05-27 | MCGOVERN MARK E | Director | A-Award | A | Common Stock | 12,376 | 0.00 | — | 28,449 | — | ↗ |
| 2021-05-27 | JANNEY DANIEL | Director | A-Award | A | Common Stock | 12,376 | 0.00 | — | 23,449 | — | ↗ |
| 2021-05-27 | GOTTO ANTONIO M JR MD D PHIL | Director | A-Award | A | Common Stock | 12,376 | 0.00 | — | 23,449 | — | ↗ |
| 2021-05-27 | Fuhrman Alan | Director | A-Award | A | Common Stock | 12,376 | 0.00 | — | 25,254 | — | ↗ |
| 2021-05-27 | Berkowitz Jeffrey | Director | A-Award | A | Common Stock | 12,376 | 0.00 | — | 23,449 | — | ↗ |
| 2021-05-24 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 20.22 | 2.02M | 4,477,964 | — | ↗ |
| 2021-05-19 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 200,000 | 20.37 | 4.07M | 4,377,964 | — | ↗ |
| 2021-05-17 | Koenig Sheldon L. | Director / Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 20.87 | 2.50M | 120,000 | — | ↗ |
| 2021-05-06 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 80,000 | 20.57 | 1.65M | 4,177,964 | — | ↗ |
| 2021-05-05 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 20.02 | 3.00M | 4,097,964 | — | ↗ |
| 2021-01-28 | MAYLEBEN TIMOTHY M | Director / Officer | A-Award | A | Stock Option (right to buy) | 175,000 | 32.12 | 5.62M | 175,000 | — | ↗ |
| 2021-01-28 | Koenig Sheldon L. | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 32.12 | 4.82M | 150,000 | — | ↗ |
| 2021-01-28 | Hall Ashley | Officer | A-Award | A | Stock Option (right to buy) | 31,000 | 32.12 | 995.7K | 31,000 | — | ↗ |
| 2021-01-28 | Bartram Richard | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 32.12 | 1.61M | 50,000 | — | ↗ |
| 2020-12-30 | MAYLEBEN TIMOTHY M | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 10,700 | 2.10 | 22.4K | 262,959 | — | ↗ |
| 2020-12-15 | Koenig Sheldon L. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-11-03 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 200,000 | 25.31 | 5.06M | 3,947,964 | — | ↗ |
| 2020-05-28 | Woody Tracy M | Director | A-Award | A | Common Stock | 6,106 | 0.00 | — | 16,040 | — | ↗ |
| 2020-05-28 | VITULLO NICOLE | Director | A-Award | A | Common Stock | 6,106 | 0.00 | — | 19,392 | — | ↗ |
| 2020-05-28 | Shepard Jay | Director | A-Award | A | Common Stock | 6,106 | 0.00 | — | 11,073 | — | ↗ |
| 2020-05-28 | MCGOVERN MARK E | Director | A-Award | A | Common Stock | 6,106 | 0.00 | — | 16,073 | — | ↗ |
| 2020-05-28 | JANNEY DANIEL | Director | A-Award | A | Common Stock | 6,106 | 0.00 | — | 11,073 | — | ↗ |
| 2020-05-28 | GOTTO ANTONIO M JR MD D PHIL | Director | A-Award | A | Common Stock | 6,106 | 0.00 | — | 11,073 | — | ↗ |
| 2020-05-28 | Fuhrman Alan | Director | A-Award | A | Common Stock | 1,221 | 0.00 | — | 12,878 | — | ↗ |
| 2020-05-28 | Berkowitz Jeffrey | Director | A-Award | A | Common Stock | 6,106 | 0.00 | — | 11,073 | — | ↗ |
| 2020-05-15 | Fuhrman Alan | Director | A-Award | A | Common Stock | 11,003 | 0.00 | — | 11,657 | — | ↗ |
| 2020-03-16 | Fuhrman Alan | Director | — | D | Common Stock | 0 | 0.00 | — | 654 | — | ↗ |
| 2020-03-11 | MAYLEBEN TIMOTHY M | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 43.00 | 107.5K | 111,998 | — | ↗ |
| 2020-02-28 | MAYLEBEN TIMOTHY M | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 49.00 | 245.0K | 109,498 | — | ↗ |
| 2020-02-26 | Hall Ashley | Officer | — | D | Stock Option (right to buy) | 14,000 | 66.50 | 931.0K | 0 | — | ↗ |
| 2020-01-23 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 20,000 | 52.12 | 1.04M | 3,747,964 | — | ↗ |
| 2020-01-02 | MAYLEBEN TIMOTHY M | Director / Officer | A-Award | A | Stock Option (right to buy) | 104,175 | 61.34 | 6.39M | 104,175 | — | ↗ |
| 2020-01-02 | Glickman Mark A | Officer | A-Award | A | Common Stock | 5,925 | 0.00 | — | 25,925 | — | ↗ |
| 2020-01-02 | Bartram Richard | Officer | A-Award | A | Stock Option (right to buy) | 33,900 | 61.34 | 2.08M | 33,900 | — | ↗ |
| 2019-11-15 | MAYLEBEN TIMOTHY M | Director / Officer | G-Gift | D | Common Stock | 365 | 0.00 | — | 81,348 | — | ↗ |
| 2019-11-11 | MAYLEBEN TIMOTHY M | Director / Officer | G-Gift | D | Common Stock | 1,950 | 0.00 | — | 81,173 | — | ↗ |
| 2019-11-06 | MAYLEBEN TIMOTHY M | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 36.98 | 184.9K | 83,663 | — | ↗ |
| 2019-11-06 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 75,000 | 37.30 | 2.80M | 3,727,964 | — | ↗ |
| 2019-09-06 | MAYLEBEN TIMOTHY M | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 35.25 | 88.1K | 78,663 | — | ↗ |
| 2019-09-04 | MAYLEBEN TIMOTHY M | Director / Officer | P-Purchase | A | Common Stock | 4,852 | 34.22 | 166.0K | 76,015 | — | ↗ |
| 2019-09-04 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 80,000 | 33.78 | 2.70M | 3,652,964 | — | ↗ |
| 2019-08-01 | MAYLEBEN TIMOTHY M | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 39.56 | 197.8K | 71,163 | — | ↗ |
| 2019-07-23 | BIOTECH TARGET N V | 10% Owner | P-Purchase | A | Common Stock | 50,000 | 42.65 | 2.13M | 3,572,964 | — | ↗ |
| 2019-06-28 | MAYLEBEN TIMOTHY M | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 46.00 | 230.0K | 66,163 | — | ↗ |
| 2019-05-29 | Woody Tracy M | Director | A-Award | A | Common Stock | 9,934 | 0.00 | — | 9,934 | — | ↗ |
| 2019-05-29 | VITULLO NICOLE | Director | A-Award | A | Common Stock | 4,967 | 0.00 | — | 13,286 | — | ↗ |
| 2019-05-29 | Shepard Jay | Director | A-Award | A | Common Stock | 4,967 | 0.00 | — | 4,967 | — | ↗ |
| 2019-05-29 | MCGOVERN MARK E | Director | A-Award | A | Common Stock | 4,967 | 0.00 | — | 9,967 | — | ↗ |
| 2019-05-29 | JANNEY DANIEL | Director | A-Award | A | Common Stock | 4,967 | 0.00 | — | 4,967 | — | ↗ |
| 2019-05-29 | GOTTO ANTONIO M JR MD D PHIL | Director | A-Award | A | Common Stock | 4,967 | 0.00 | — | 4,967 | — | ↗ |
| 2019-05-29 | Braunstein Scott | Director | A-Award | A | Common Stock | 4,967 | 0.00 | — | 5,019 | — | ↗ |
| 2019-05-29 | Berkowitz Jeffrey | Director | A-Award | A | Common Stock | 4,967 | 0.00 | — | 4,967 | — | ↗ |
Executive team
Top executives
EBIT / Employee
198.3K
Shares Outstanding
207.91M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Sheldon L. Koenig President and Chief Executive Officer | 770.8K | — | 1.26M | 847.9K | 639.4K | 17.4K | 3.54M | 59.62% | ↗ |
| 2 | 2025 | John B. Harlow, Jr. Chief Commercial Officer | 66.9K | 35.0K | 1.61M | 1.10M | — | 769.00 | 2.81M | 96.35% | ↗ |
| 3 | 2025 | Benjamin Halladay Chief Financial Officer | 495.8K | — | 357.0K | 239.9K | 247.5K | 11.8K | 1.35M | 44.15% | ↗ |
| 4 | 2024 | Sheldon L. Koenig President and Chief Executive Officer | 745.8K | — | 930.7K | 982.2K | 487.5K | 29.0K | 3.18M | 60.24% | ↗ |
| 5 | 2024 | JoAnne Foody Chief Medical Officer | 388.3K | — | 307.5K | 383.7K | 195.2K | 595.9K | 1.87M | 36.95% | ↗ |
| 6 | 2024 | Benjamin Halladay Chief Financial Officer | 467.3K | — | 348.5K | 306.0K | 235.1K | 11.5K | 1.37M | 47.83% | ↗ |
| 7 | 2024 | Benjamin Halladay Chief Financial Officer | 467.3K | — | 348.5K | 306.0K | 235.1K | 11.5K | 1.37M | 47.83% | ↗ |
| 8 | 2024 | Eric Warren Chief Commercial Officer | 481.9K | — | 205.0K | 229.5K | 218.3K | 15.3K | 1.15M | 37.79% | ↗ |
| 9 | 2024 | Benjamin Looker General Counsel | 471.0K | — | 205.0K | 229.5K | 213.8K | 11.6K | 1.13M | 38.42% | ↗ |
| 10 | 2023 | Sheldon L. Koenig President and Chief Executive Officer | 720.8K | — | 422.1K | 1.27M | 541.9K | 16.0K | 2.97M | 56.92% | ↗ |
| 11 | 2023 | JoAnne Foody Chief Medical Officer | 528.3K | — | 115.6K | 452.3K | 306.5K | 22.1K | 1.42M | 39.86% | ↗ |
| 12 | 2023 | Eric Warren Chief Commercial Officer | 462.5K | — | 89.6K | 269.2K | 241.3K | 15.1K | 1.08M | 33.30% | ↗ |
| 13 | 2023 | Eric Warren Chief Commercial Officer | 462.5K | — | 89.6K | 269.2K | 241.3K | 15.1K | 1.08M | 33.30% | ↗ |
| 14 | 2022 | Sheldon L. Koenig President and Chief Executive Officer | 683.3K | — | 549.8K | 2.05M | 500.5K | 13.6K | 3.80M | 68.48% | ↗ |
| 15 | 2022 | JoAnne Foody Chief Medical Officer | 505.0K | — | 132.7K | 627.2K | 250.0K | 16.2K | 1.53M | 49.63% | ↗ |
| 16 | 2022 | Benjamin Looker General Counsel | 375.0K | — | 258.4K | 485.0K | 165.0K | 10.4K | 1.29M | 57.46% | ↗ |
| 17 | 2022 | General Counsel | 375.0K | — | 258.4K | 485.0K | 165.0K | 10.4K | 1.29M | 57.46% | ↗ |
| 18 | 2021 | Tim M. Mayleben Former Chief Executive Officer | 265.2K | — | — | 3.99M | — | 3.98M | 8.23M | 48.45% | ↗ |
| 19 | 2021 | Sheldon L. Koenig President and Chief Executive Officer | 565.9K | — | 1.62M | 5.43M | 150.0K | 13.0K | 7.78M | 90.63% | ↗ |
| 20 | 2021 | JoAnne Foody Chief Medical Officer | 258.2K | 100.0K | 1.61M | 1.60M | 113.6K | — | 3.68M | 87.19% | ↗ |
| 21 | 2021 | JoAnne Foody Chief Medical Officer | 258.2K | 100.0K | 1.61M | 1.60M | 113.6K | — | 3.68M | 87.19% | ↗ |
| 22 | 2021 | Chief Medical Officer | 258.2K | 100.0K | 1.61M | 1.60M | 113.6K | — | 3.68M | 87.19% | ↗ |
| 23 | 2021 | Richard B. Bartram Former Chief Financial Officer | 411.7K | — | 922.3K | 1.90M | 84.0K | 9.8K | 3.32M | 84.79% | ↗ |
| 24 | 2021 | Ashley Hall Former Chief Development Officer | 270.1K | — | 650.5K | 1.13M | — | 822.6K | 2.88M | 62.02% | ↗ |
| 25 | 2020 | Tim M. Mayleben President and Chief Executive Officer | 700.0K | — | 1.42M | 4.52M | 210.0K | 76.9K | 6.93M | 85.75% | ↗ |
| 26 | 2020 | Tim M. Mayleben Former Chief Executive Officer | 700.0K | — | 1.42M | 4.52M | 210.0K | 76.9K | 6.93M | 85.75% | ↗ |
| 27 | 2020 | Richard B. Bartram Former Chief Financial Officer | 400.0K | — | 461.6K | 1.47M | 120.0K | 9.8K | 2.46M | 78.48% | ↗ |
| 28 | 2020 | Richard B. Bartram Chief Financial Officer | 400.0K | — | 461.6K | 1.47M | 120.0K | 9.8K | 2.46M | 78.48% | ↗ |
| 29 | 2020 | Mark. A Glickman Former Chief Commercial Officer | 453.4K | — | 363.4K | 1.15M | — | 382.0K | 2.35M | 64.50% | ↗ |
| 30 | 2020 | Chief Development Officer | 435.0K | 300.0K | 337.4K | 1.07M | 145.0K | 9.8K | 2.30M | 61.32% | ↗ |
| 31 | 2020 | Ashley Hall Former Chief Development Officer | 435.0K | 300.0K | 337.4K | 1.07M | 145.0K | 9.8K | 2.30M | 61.32% | ↗ |
| 32 | 2020 | Ashley Hall Former Chief Development Officer | 435.0K | 300.0K | 337.4K | 1.07M | 145.0K | 9.8K | 2.30M | 61.32% | ↗ |
| 33 | 2020 | Sheldon L. Koenig President and Chief Executive Officer | 23.2K | — | — | — | — | — | 23.2K | 0.00% | ↗ |
| 34 | 2020 | Sheldon L. Koenig President and Chief Executive Officer | 23.2K | — | — | — | — | — | 23.2K | 0.00% | ↗ |
| 35 | 2020 | Chief Operating Officer | 23.2K | — | — | — | — | — | 23.2K | 0.00% | ↗ |
| 36 | 2019 | Tim M. Mayleben President and Chief Executive Officer | 625.0K | — | — | — | 375.0K | 80.9K | 1.08M | 0.00% | ↗ |
| 37 | 2019 | Tim M. Mayleben Former Chief Executive Officer | 625.0K | — | — | — | 375.0K | 80.9K | 1.08M | 0.00% | ↗ |
| 38 | 2019 | Mark. A Glickman Former Chief Commercial Officer | 440.0K | — | — | — | 176.0K | 8.4K | 624.4K | 0.00% | ↗ |
| 39 | 2019 | Mark. A Glickman Chief Commercial Officer | 440.0K | — | — | — | 176.0K | 8.4K | 624.4K | 0.00% | ↗ |
| 40 | 2019 | Richard B. Bartram Chief Financial Officer | 340.0K | — | — | — | 136.0K | 9.5K | 485.5K | 0.00% | ↗ |
| 41 | 2019 | Richard B. Bartram Former Chief Financial Officer | 340.0K | — | — | — | 136.0K | 9.5K | 485.5K | 0.00% | ↗ |
| 42 | 2018 | Tim M. Mayleben President and Chief Executive Officer | 600.0K | 115.0K | — | 8.57M | 360.0K | 81.6K | 9.72M | 88.11% | ↗ |
| 43 | 2018 | Mark. A Glickman Chief Commercial Officer | 322.5K | — | 1.35M | 7.15M | 190.0K | 9.3K | 9.01M | 94.21% | ↗ |
| 44 | 2018 | Mark. A Glickman Former Chief Commercial Officer | 322.5K | — | 1.35M | 7.15M | 190.0K | 9.3K | 9.01M | 94.21% | ↗ |
| 45 | 2018 | Mark. A Glickman Chief Commercial Officer | 322.5K | — | 1.35M | 7.15M | 190.0K | 9.3K | 9.01M | 94.21% | ↗ |
| 46 | 2018 | Richard B. Bartram Chief Financial Officer | 330.0K | — | — | 2.11M | 90.0K | 9.3K | 2.54M | 83.10% | ↗ |
| 47 | 2018 | Richard B. Bartram Chief Financial Officer | 330.0K | — | — | 2.11M | 90.0K | 9.3K | 2.54M | 83.10% | ↗ |
| 48 | 2018 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research and | 430.0K | — | — | 1.86M | 43.0K | 12.3K | 2.35M | 79.31% | ↗ |
| 49 | 2017 | Tim M. Mayleben President and Chief Executive Officer | 557.5K | — | — | 3.96M | 404.0K | 89.8K | 5.01M | 79.03% | ↗ |
| 50 | 2017 | Mary P. McGowan, M.D. Chief Medical Officer | 395.0K | — | — | 2.69M | — | 12.0K | 3.10M | 86.86% | ↗ |
| 51 | 2017 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research and Development | 390.0K | — | — | 644.0K | 203.0K | 12.0K | 1.25M | 51.56% | ↗ |
| 52 | 2016 | Tim M. Mayleben President and Chief Executive Officer | 535.0K | — | — | 417.5K | 176.0K | 85.4K | 1.21M | 34.39% | ↗ |
| 53 | 2016 | Tim M. Mayleben, President and Chief Executive Officer | 535.0K | — | — | 417.5K | 176.0K | 85.4K | 1.21M | 34.39% | ↗ |
| 54 | 2016 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research and Development | 390.0K | — | — | 208.7K | — | 12.0K | 695.7K | 30.00% | ↗ |
| 55 | 2016 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research and Development and Chief | 390.0K | — | — | 208.7K | 85.0K | 12.0K | 695.7K | 30.00% | ↗ |
| 56 | 2016 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research and | 390.0K | — | — | 208.7K | 85.0K | 12.0K | 695.7K | 30.00% | ↗ |
| 57 | 2016 | Mary P. McGowan, M.D. Chief Medical Officer | 395.0K | — | — | 208.7K | — | 11.4K | 690.1K | 30.25% | ↗ |
| 58 | 2016 | Roger S. Newton, Ph.D., FAHA, Executive Chairman and Chief Scientific Officer | 348.6K | — | — | — | — | 10.0K | 358.6K | 0.00% | ↗ |
| 59 | 2015 | Mary P. McGowan, M.D. Chief Medical Officer | 203.1K | 61.0K | 863.1K | 7.56M | — | — | 8.68M | 96.96% | ↗ |
| 60 | 2015 | Mary P. McGowan, M.D. Chief Medical Officer | 203.1K | 61.0K | 863.1K | — | — | — | 8.68M | 9.94% | ↗ |
| 61 | 2015 | Tim M. Mayleben President and Chief Executive Officer | 480.0K | 228.0K | — | 5.01M | — | 34.4K | 5.75M | 87.09% | ↗ |
| 62 | 2015 | Tim M. Mayleben, President and Chief Executive Officer | 480.0K | 228.0K | — | 5.01M | — | 34.4K | 5.75M | 87.09% | ↗ |
| 63 | 2015 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research and Development | 370.0K | 127.0K | — | 2.72M | — | 12.0K | 3.23M | 84.25% | ↗ |
| 64 | 2015 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research and Development and Chief | 370.0K | 127.0K | — | 2.72M | — | 12.0K | 3.23M | 84.25% | ↗ |
| 65 | 2015 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research | 370.0K | 127.0K | — | 2.72M | — | 12.0K | 3.23M | 84.25% | ↗ |
| 66 | 2015 | Roger S. Newton, Ph.D., FAHA, Executive Chairman and Chief Scientific Officer | 375.0K | — | — | 1.01M | — | — | 1.38M | 72.90% | ↗ |
| 67 | 2014 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research and Development and Chief | 150.0K | — | — | 2.84M | 70.0K | 146.8K | 3.21M | 88.57% | ↗ |
| 68 | 2014 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research | 150.0K | — | — | 2.84M | 70.0K | 146.8K | 3.21M | 88.57% | ↗ |
| 69 | 2014 | Narendra D. Lalwani, Ph.D., FAHA, DABT Executive Vice President, Research and Development | 150.0K | — | — | 2.84M | 70.0K | 146.8K | 3.06M | 92.82% | ↗ |
| 70 | 2014 | Tim M. Mayleben, President and Chief Executive Officer | 450.0K | — | — | — | 300.0K | — | 750.0K | 0.00% | ↗ |
| 71 | 2014 | Roger S. Newton, Ph.D., FAHA, Executive Chairman and Chief Scientific Officer | 375.0K | — | — | — | 50.0K | — | 425.0K | 0.00% | ↗ |
| 72 | 2013 | Tim M. Mayleben, President and Chief Executive Officer | 400.0K | — | — | 2.89M | 160.0K | — | 3.45M | 83.77% | ↗ |
| 73 | 2013 | Roger S. Newton, Ph.D., FAHA, Executive Chairman and Chief Scientific Officer | 375.0K | — | — | 1.30M | 150.0K | — | 1.83M | 71.31% | ↗ |
| 74 | 2013 | Noah L. Rosenberg, M.D., Chief Medical Officer | 335.0K | — | — | 153.8K | — | — | 488.8K | 31.47% | ↗ |
| 75 | 2012 | Roger S. Newton, Ph.D., FAHA, Executive Chairman and Chief Scientific Officer | 369.8K | — | — | — | — | — | 369.8K | 0.00% | ↗ |
| 76 | 2012 | Noah L. Rosenberg, M.D., Chief Medical Officer | 303.3K | 15.0K | — | 89.6K | — | — | 318.3K | 28.14% | ↗ |
| 77 | 2012 | Tim M. Mayleben, President and Chief Executive Officer | 25.0K | — | — | — | — | — | 25.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sheldon L. Koenig | President, Chief Executive Officer & Director | 1M | male |
| Benjamin Halladay | Chief Financial Officer | 755.1K | male |
| Benjamin O. Looker | Chief Legal and Corporate Affairs Officer | 696.4K | male |
| John Harlow | Chief Commercial Officer | 582.9K | male |
| Glenn Brame | Chief Technical Operations Officer | — | male |
| LeAnne Bloedon | Vice President & Head of Development | — | — |
| Betty Jean Swartz | Chief Business Officer | — | female |
| Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development | — | — |
| Tiffany Aldrich | Associate Director of Corporate Communications | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ESPR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
